Faheem Hasnain
CIK 1352620 · President & CEO · last filed 2026-08-26
Faheem Hasnain is a President & CEO who has filed 95 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for GOSS, was dated Aug 26, 2026. Across all open-market trades the lifetime net is −$20.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $8.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.95M
12
95
-$20.89M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GOSS | President & CEO | 6,245,866 | $0.17 | $1.05M | $3.22M | 22 | 2026-08-26 |
| KURA | Director | 23,983 | $12.89 | $309.1K | -$291.2K | 13 | 2026-06-04 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 10,791 | $58.70 | $633.4K | $300.0K | 8 | 2024-01-23 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 55,000 | $0.01 | $280 | $0 | 1 | 2021-02-26 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | 16,114 | — | — | $1.20M | 5 | 2019-10-04 |
| Receptos, Inc. (RCPT) Delisted | President & CEO | 0 | — | — | -$21.89M | 5 | 2015-08-27 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 3 | 2014-11-12 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 24,519 | — | — | $0 | 7 | 2013-01-03 |
| FACT | President & CEO | 102,667 | $10.70 | $1.10M | $0 | 4 | 2010-04-21 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | President & CEO | 125,000 | — | — | $0 | 1 | 2008-10-03 |
| BIIB | EVP, Oncology/Rheumatology SBU | 25,454 | $216.04 | $5.50M | -$3.43M | 12 | 2008-07-10 |
| TERCICA INC (TRCA) Delisted | Director | — | $7.87 | — | $0 | 1 | 2008-02-28 |
Recent Filings
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-26 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2026-06-04 | KURA | Grant (A) | — | $0 | EDGAR |
| 2026-03-20 | GOSS | Mixed | — | $0 | EDGAR |
| 2026-01-05 | GOSS | Grant (A) | +280,000 | $0 | EDGAR |
| 2025-12-10 | KURA | Mixed | — | -$78.6K | EDGAR |
| 2025-12-09 | KURA | Notice (144) | −10,000 | -$116.4K | EDGAR |
| 2025-10-02 | GOSS | Grant (A) | +437,500 | $0 | EDGAR |
| 2025-06-06 | KURA | Grant (A) | — | $0 | EDGAR |
| 2025-03-24 | KURA | Mixed | — | -$38.1K | EDGAR |
| 2025-03-21 | KURA | Notice (144) | −30,000 | -$235.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.